<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081676</url>
  </required_header>
  <id_info>
    <org_study_id>H-16038140</org_study_id>
    <nct_id>NCT03081676</nct_id>
  </id_info>
  <brief_title>The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea</brief_title>
  <acronym>HNF1A-Clamp</acronym>
  <official_title>The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young
      type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes. The aim of this study is to
      evaluate the effects of supra-physiological levels of GIP and GLP-1, respectively, on insulin
      and glucagon secretion at fasting plasma glucose (FPG) and &quot;post-prandial&quot; PG levels (1.5 ×
      FPG) in patients with HNF1A-diabetes and matched healthy controls treated with or without a
      low dose of glimepiride (sulphonylurea). In addition, we will evaluate the maximal insulin
      and glucagon secretory capacity in both groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 6 experimental days will be performed. The following is an outline of an
      experimental day:

      Participants will meet after a 10-hour fast. A tablet of glimepiride 1.0 mg or placebo will
      be administered 90 minutes before the initiation of the experiment (-90 minutes) The mean FPG
      will be calculated from blood samples -105, -100 and -90 minutes. Two intravenous cannulas
      will be inserted in a cubital vein of each arm. One intravenous cannula will be used for
      infusions of glucose, arginine and GIP and the other will be used to collect venous blood.
      The forearm from which blood samples are drawn will be placed in a heating pad (50°C)
      throughout the experiment for arterialisation of venous blood.

      At time 0 minutes, a glucose clamp will be established at the FPG level for 60 minutes and
      hereafter a post-prandial clamp period of 1.5 × FPG for another 60 minutes. At time 120
      minutes, a bolus of 5g of L-arginine (given as 50% arginine HCl) will be infused during 30
      seconds. The post-prandial clamp will be maintained for another 10 minutes until time 130
      minutes to prevent reactive hypoglycaemia. Throughout the experiment (0-130 minutes) a
      continuous infusion of either GIP (1.5 pmol/kg/min), GLP-1 (0.5 pmol/kg/min) or placebo
      (saline) will be administered.

      During the experiment PG will be kept stable by a continuous 20%-glucose infusion. The rate
      of infusion will be regulated according to PG determined by bed-site measurements every 5
      minutes. After 60 minutes, a post-prandial clamp will be established by a bolus infusion over
      one minute using 50%-glucose to target 1.5 × FPG (the amount of glucose to be administered
      will calculated as follows: (1.5 × FPG - FPG) × 35 mg glucose × weight in kilogram).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>0-120 minutes</time_frame>
    <description>Incremental area under the curve (iAUC) for plasma insulin at time 0-60 minutes, time 60-120 minutes and time 0-120 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>0-120 minutes</time_frame>
    <description>Incremental area under the curve (iAUC) for plasma glucagon at time 0-60 minutes, time 60-120 minutes and time 0-120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal insulin secretion</measure>
    <time_frame>120-125 minutes</time_frame>
    <description>Arginine maximal insulin secretion test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal glucagon secretion</measure>
    <time_frame>120-125 minutes</time_frame>
    <description>Arginine maximal glucagon secretion test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPP-4 activity</measure>
    <time_frame>0-120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount glucose used to maintain the glucose clamp</measure>
    <time_frame>0-130 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Maturity-Onset Diabetes of the Young, Type 3</condition>
  <arm_group>
    <arm_group_label>Glimepiride + GIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet Glimepiride + infusion of GIP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + GIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo tablet + infusion of GIP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride + GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride + infusion of GLP-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo tablet + infusion of GLP-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride + infusion of placebo (saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablel + infusion of placebo (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride 1Mg Tablet</intervention_name>
    <description>Glimepiride</description>
    <arm_group_label>Glimepiride + GIP</arm_group_label>
    <arm_group_label>Glimepiride + GLP-1</arm_group_label>
    <arm_group_label>Glimepiride + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-like Peptide-1</intervention_name>
    <description>GLP-1 infusion</description>
    <arm_group_label>Glimepiride + GLP-1</arm_group_label>
    <arm_group_label>Placebo + GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose-Dependent Insulinotropic Polypeptide</intervention_name>
    <description>GIP-infusion</description>
    <arm_group_label>Glimepiride + GIP</arm_group_label>
    <arm_group_label>Placebo + GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo + GIP</arm_group_label>
    <arm_group_label>Placebo + GLP-1</arm_group_label>
    <arm_group_label>Placebo + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo (saline)</description>
    <arm_group_label>Glimepiride + Placebo</arm_group_label>
    <arm_group_label>Placebo + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants

        Ten patients with HNF1A-diabetes and ten matched healthy controls will be recruited.
        Different inclusion and exclusion criteria applies for the two groups:

        Inclusion criteria for HNF1A-patients

          -  Patients with HNF1A-diabetes verified by genetic testing

          -  Patients treated with diet or sulphonylurea monotherapy

          -  Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l)

          -  Informed consent

        Exclusion criteria for HNF1A-patients

          -  Nephropathy (estimated glomerular filtration rate (eGFR) &lt;60 ml/min/1.73m2 and/or
             albuminuria)

          -  Liver disease (serum alanine aminotransferase (ALT) and/or serum aspartate
             aminotransferase (AST) above 2 × normal values)

          -  Pregnancy or breastfeeding

        Inclusion criteria for healthy controls

          -  FPG ≤6 mmol/l and glycated haemoglobin (HbA1c) ≤43 mmol/mol

          -  Normal haemoglobin as defined above

          -  Age ≥18 years

          -  Informed consent

        Exclusion criteria for healthy controls

          -  No family history of type 1 or type 2 diabetes

          -  Nephropathy (defined above)

          -  Liver disease (defined above)

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Sidelmann Christensen</last_name>
    <phone>+0045 6167 1662</phone>
    <email>alexander.sidelmann.christensen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Diabetes Research, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Sidelmann Christensen, MD, ph.d.-student</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Alexander Christensen</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>Maturity-Onset Diabetes of the Young, Type 3</keyword>
  <keyword>Glucose-dependent insulinotropic peptide</keyword>
  <keyword>Glucagon-like-peptide 1</keyword>
  <keyword>Dipeptidyl peptidase 4</keyword>
  <keyword>Glimepiride</keyword>
  <keyword>Sulphonylurea</keyword>
  <keyword>Glucose clamp</keyword>
  <keyword>Hepatocyte nuclear factor 1 alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

